J S Wunder

Summary

Affiliation: Samuel Lunenfeld Research Institute
Country: Canada

Publications

  1. ncbi TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study
    Jay S Wunder
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5
    J Clin Oncol 23:1483-90. 2005
  2. ncbi Opportunities for improving the therapeutic ratio for patients with sarcoma
    Jay S Wunder
    University Musculoskeletal Oncology Unit and Program in Molecular Biology and Cancer, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada
    Lancet Oncol 8:513-24. 2007
  3. ncbi Comparison of two methods of reconstruction for primary malignant tumors at the knee: a sequential cohort study
    J S Wunder
    University Musculoskeletal Oncology Unit, Mount Sinai Hospital, and the Department of Surgery, University of Toronto, Toronto, Canada
    J Surg Oncol 77:89-99; discussion 100. 2001
  4. ncbi The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma
    J S Wunder
    Department of Surgery, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York City, NY 10021, USA
    J Bone Joint Surg Am 80:1020-33. 1998
  5. ncbi MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study
    J S Wunder
    Samuel Lunenfeld Research Institute and the University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, Canada
    J Clin Oncol 18:2685-94. 2000
  6. ncbi Predictors of functional outcomes following limb salvage surgery for lower-extremity soft tissue sarcoma
    A M Davis
    University Musculoskeletal Oncology Unit, Mount Sinai Hospital and the University of Toronto, Toronto, Canada
    J Surg Oncol 73:206-11. 2000
  7. ncbi Allograft reconstruction of the acetabulum after resection of stage-IIB sarcoma. Intermediate-term results
    R S Bell
    University Musculoskeletal Oncology Unit, Mount Sinai Hospital and the University of Toronto, Ontario, Canada
    J Bone Joint Surg Am 79:1663-74. 1997
  8. ncbi Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence
    C H Gerrand
    Mount Sinai Hospital, Toronto, Canada
    J Bone Joint Surg Br 83:1149-55. 2001
  9. ncbi p53 missense but not truncation mutations are associated with low levels of p21(CIP1/WAF1) mRNA expression in primary human sarcomas
    S Mousses
    Samuel Lunenfeld Research Institute, Department of Laboratory Medicine and Pathobiology, Mount Sinai Hospital, Toronto, Ontario, Canada
    Br J Cancer 84:1635-9. 2001
  10. ncbi Instability after major tumor resection: prevention and treatment
    C H Gerrand
    The University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, Canada
    Orthop Clin North Am 32:697-710, ix-x. 2001

Collaborators

Detail Information

Publications53

  1. ncbi TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study
    Jay S Wunder
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5
    J Clin Oncol 23:1483-90. 2005
    ..This is the first prospective study of the prognostic value of somatic TP53 mutations in patients with newly diagnosed extremity osteosarcoma...
  2. ncbi Opportunities for improving the therapeutic ratio for patients with sarcoma
    Jay S Wunder
    University Musculoskeletal Oncology Unit and Program in Molecular Biology and Cancer, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada
    Lancet Oncol 8:513-24. 2007
    ..Research in stem-cell biology and nanotechnology holds promise for additional novel treatment options in the future...
  3. ncbi Comparison of two methods of reconstruction for primary malignant tumors at the knee: a sequential cohort study
    J S Wunder
    University Musculoskeletal Oncology Unit, Mount Sinai Hospital, and the Department of Surgery, University of Toronto, Toronto, Canada
    J Surg Oncol 77:89-99; discussion 100. 2001
    ....
  4. ncbi The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma
    J S Wunder
    Department of Surgery, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York City, NY 10021, USA
    J Bone Joint Surg Am 80:1020-33. 1998
    ..These indicators should be used to identify patients who are at high risk for metastasis as such patients may be candidates for more intensive or novel therapies...
  5. ncbi MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study
    J S Wunder
    Samuel Lunenfeld Research Institute and the University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, Canada
    J Clin Oncol 18:2685-94. 2000
    ..This study represents the first prospective assessment of the prognostic value of MDR1 mRNA expression in patients with newly diagnosed extremity osteosarcoma...
  6. ncbi Predictors of functional outcomes following limb salvage surgery for lower-extremity soft tissue sarcoma
    A M Davis
    University Musculoskeletal Oncology Unit, Mount Sinai Hospital and the University of Toronto, Toronto, Canada
    J Surg Oncol 73:206-11. 2000
    ....
  7. ncbi Allograft reconstruction of the acetabulum after resection of stage-IIB sarcoma. Intermediate-term results
    R S Bell
    University Musculoskeletal Oncology Unit, Mount Sinai Hospital and the University of Toronto, Ontario, Canada
    J Bone Joint Surg Am 79:1663-74. 1997
    ..In the present series, more than half of the patients either died or had failure of the reconstruction...
  8. ncbi Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence
    C H Gerrand
    Mount Sinai Hospital, Toronto, Canada
    J Bone Joint Surg Br 83:1149-55. 2001
    ..2% and 3.6%) and the two high-risk groups (31.6% and 37.5%). This classification therefore provides useful information about the incidence of local recurrence after positive-margin resection...
  9. ncbi p53 missense but not truncation mutations are associated with low levels of p21(CIP1/WAF1) mRNA expression in primary human sarcomas
    S Mousses
    Samuel Lunenfeld Research Institute, Department of Laboratory Medicine and Pathobiology, Mount Sinai Hospital, Toronto, Ontario, Canada
    Br J Cancer 84:1635-9. 2001
    ..The results of this study suggest that different types of p53 mutations can have different effects on the expression of downstream genes such as p21(CIP1/WAF1) in human sarcomas...
  10. ncbi Instability after major tumor resection: prevention and treatment
    C H Gerrand
    The University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, Canada
    Orthop Clin North Am 32:697-710, ix-x. 2001
    ..The options for reconstruction in each area are discussed along with a review of the literature and a description of the authors' preferred approach...
  11. ncbi The influence of anatomic location on functional outcome in lower-extremity soft-tissue sarcoma
    C H Gerrand
    University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, Canada
    Ann Surg Oncol 11:476-82. 2004
    ..Anatomical location is not a significant predictor of aggregated MSTS and TESS evaluations. However, there is variation in MSTS and TESS item scores across anatomical locations...
  12. ncbi Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma
    N Gokgoz
    Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Cancer 92:2181-9. 2001
    ..The current data indicate that p53 mutations are not late events in osteosarcoma tumor progression, because they are evident before the development of metastases. The inclusion of exons 4 and 10 increased the sensitivity of the analysis...
  13. ncbi Topotecan and cyclophosphamide in adults with relapsed sarcoma
    P Blanchette
    Department of Internal Medicine, University of Toronto, Toronto, Canada
    Sarcoma 2012:749067. 2012
    ..7 months, all but 1 patient had died of disease. Conclusion: TC combination is tolerable but has only modest activity in adults with recurrent sarcoma. Other regimens deserve exploration for this high-risk group of patients...
  14. ncbi Soft tissue sarcomas involving the pelvis
    S J Lewis
    University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Department of Surgical Oncology, Toronto, Ontario, Canada
    J Surg Oncol 77:8-14; discussion 15. 2001
    ..CONCLUSIONS: Soft tissue sarcoma of the pelvis is fortunately a rare disease with a high risk of local and systemic disease progression despite treatment with irradiation and surgical resection...
  15. ncbi The efficacy of chemical adjuvants on giant-cell tumour of bone. An in vitro study
    Y Gortzak
    Mount Sinai Hospital, Toronto, Canada
    J Bone Joint Surg Br 92:1475-9. 2010
    ..No multinucleated cell formation was seen in these cultures. These results suggest that the use of chemical adjuvants other than water could help improve local control in the treatment of GCT of bone...
  16. ncbi Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma
    H Al-Hussaini
    Division of Medical Oncology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada M5G 2M9
    Sarcoma 2011:231789. 2011
    ..Conclusions. Patients with localized SS have a good chance of cure with surgery and RT. Evidence for a well-defined role of chemotherapy to improve survival In localized SS remains elusive...
  17. ncbi Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma
    A M Davis
    Toronto Rehabilitation Institute, Princess Margaret Hospital, University of Toronto, Ontario, Canada
    J Clin Oncol 20:4472-7. 2002
    ..Functional outcome and health status of extremity STS patients randomized in a phase III trial comparing preoperative versus postoperative RT is described...
  18. ncbi Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas
    J S Wunder
    Department of Surgery, University of Toronto, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Canada
    Oncogene 18:783-8. 1999
    ..The different patterns of gene amplification and overexpression of CDK4, SAS and MDM2 in parosteal and intramedullary osteosarcomas may help explain the disparity in the biological behaviour of these two types of osteosarcoma...
  19. ncbi Transarticular invasion of bone tumours across the sacroiliac joint
    S Chhaya
    Department of Medical Imaging, Mount Sinai Hospital and the University Health Network, University of Toronto, Toronto, Canada
    Skeletal Radiol 34:771-7. 2005
    ....
  20. ncbi Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma
    Salvador Mejia-Guerrero
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada
    Genes Chromosomes Cancer 49:518-25. 2010
    ..There was no association with other clinical parameters. In conclusion, co-amplification of MDM2 and CDK4 in two separate amplicons occurs frequently in parosteal OS and less so in classical high-grade OS...
  21. ncbi Free tissue transfer and deep vein thrombosis
    Dylan J Murray
    Division of Plastic Surgery, University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Plast Reconstr Aesthet Surg 61:687-92. 2008
    ....
  22. ncbi Prognosis of radiation-induced bone sarcoma is similar to primary osteosarcoma
    Mahmood Shaheen
    University Musculoskeletal Oncology Unit, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada
    Clin Orthop Relat Res 450:76-81. 2006
    ..LEVEL OF EVIDENCE: Therapeutic study, level IV-1...
  23. ncbi Giant cell tumor of bone express p63
    Brendan C Dickson
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    Mod Pathol 21:369-75. 2008
    ..Moreover, p63 may be a useful biomarker to differentiate giant cell tumor of bone from central giant cell granuloma and other giant cell-rich tumors, such as giant cell tumor of tendon sheath and pigmented villonodular synovitis...
  24. ncbi Altered expression and deletion of RMO1 in osteosarcoma
    Kolja Eppert
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Int J Cancer 114:738-46. 2005
    ..Northern blot analysis indicated that RMO1 mRNA is ubiquitously expressed in tissues except for peripheral blood leukocytes. These data suggest that RMO1 may be a candidate for a protein involved in inhibiting tumor progression...
  25. ncbi COPS3 amplification and clinical outcome in osteosarcoma
    Taiqiang Yan
    Fred A Litwin Centre for Cancer Genetics, Mount Sinai Hospital, and University Musculoskeletal Oncology Unit, Toronto, Ontario, Canada
    Cancer 109:1870-6. 2007
    ..To determine the relation between COPS3 amplification, P53 mutation, and patient outcome in osteosarcoma, tumors from a large cohort of patients with high-grade osteosarcoma and long-term clinical follow-up were examined...
  26. ncbi Cyclin alterations in giant cell tumor of bone
    Adel Kauzman
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, M5G 1X5, Canada
    Mod Pathol 16:210-8. 2003
    ..These results suggest that alterations in cyclin D1 and/or D3 might play a role in the pathogenesis of giant cell tumor of bone...
  27. ncbi Clinical and functional outcomes of patients with a pathologic fracture in high-grade osteosarcoma
    Peter C Ferguson
    Division of Orthopaedic Surgery, Mount Sinai Hospital, Department of Surgery, University Musculoskeletal Oncology Unit, University of Toronto, Toronto, Ontario, Canada
    J Surg Oncol 102:120-4. 2010
    ..There have been variable reports of outcomes of patients with osteosarcoma and pathologic fractures. The purpose of this study was to document outcomes after management of this clinical entity at a single large oncology center...
  28. ncbi Iliosacral resection for primary bone tumors: is pelvic reconstruction necessary?
    Gordon P Beadel
    University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Orthop Relat Res 438:22-9. 2005
    ..LEVEL OF EVIDENCE: Therapeutic study, Level III-1 (case-control study). See the Guidelines for Authors for a complete description of levels of evidence...
  29. ncbi von Willebrand factor expression in osteosarcoma metastasis
    Kolja Eppert
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Mod Pathol 18:388-97. 2005
    ..These findings suggest that vWF expression is deregulated in osteosarcoma tumors, potentially contributing to metastasis...
  30. ncbi Eosinophilic granuloma. A different behaviour in children than in adults
    F Plasschaert
    Hospital for Sick Children and the Mount Sinai Hospital, Toronto, Canada
    J Bone Joint Surg Br 84:870-2. 2002
    ..By contrast, four of 13 skeletally mature patients had a recurrence and required further surgery. This suggests that eosinophilic granuloma has a low rate of recurrence in skeletally immature patients...
  31. ncbi Oncologic and functional outcome of scapular chondrosarcoma
    Anthony M Griffin
    University Musculoskeletal Oncology Unit at Mount Sinai Hospital, The University of Toronto, Suite 476G, 600 University Avenue, Toronto, Canada
    Ann Surg Oncol 15:2250-6. 2008
    ..The purpose of this study was to investigate both the oncologic and functional outcomes of patients presenting to a large oncology center with primary chondrosarcoma of the scapula...
  32. ncbi Parathyroid hormone-related protein regulates glioma-associated oncogene transcriptional activation: lessons learned from bone development and cartilage neoplasia
    Benjamin A Alman
    Program in Developmental and Stem Cell Biology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    Ann N Y Acad Sci 1144:36-41. 2008
    ..Thus, activation of a G protein-coupled receptor can negatively regulate hedgehog-mediated transcription independent of hedgehog ligand activity, raising intriguing therapeutic possibilities...
  33. ncbi Functional outcomes after treatment of aggressive tumors in the distal radius
    Shannon K T Puloski
    The University Musculoskeletal Oncology Unit, Mt Sinai Hospital, Toronto, Ontario, Canada
    Clin Orthop Relat Res 459:154-60. 2007
    ..Whenever possible, joint preservation is preferable for the result of better extremity function, but weaker grip, higher local tumor relapse, and late arthritis remain concerns...
  34. ncbi Joint salvage for pathologic fracture of giant cell tumor of the lower extremity
    Benjamin M Deheshi
    University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Orthop Relat Res 459:96-104. 2007
    ..Joint salvage for patients with pathologic fractures through giant cell tumor of weightbearing bones is a reasonable option with functional outcomes and recurrence rates comparable to those of patients without fracture...
  35. ncbi CYP3A4/5 and pharmacogenetics in patients with sarcoma - Authors' reply
    Jay S Wunder
    University Musculoskeletal Oncology Unit and Program in Molecular Biology and Cancer, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Lancet Oncol 8:668-9. 2007
  36. ncbi Gli2 and p53 cooperate to regulate IGFBP-3- mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors
    Louisa Ho
    Program in Developmental and Stem Cell Biology, Hospital for Sick Children, University of Toronto, ON, Canada
    Cancer Cell 16:126-36. 2009
    ..IGF signaling-meditated apoptosis regulates the progression to malignant chondrosarcoma...
  37. ncbi hCDC4 variation in osteosarcoma
    Taiqiang Yan
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, M5G 1X5
    Cancer Genet Cytogenet 169:138-42. 2006
    ..We conclude that somatic hCDC4 mutations are infrequent in osteosarcoma, and are unlikely to play an important role in aneuploidy of this tumor...
  38. ncbi Work status after distal femoral Kotz reconstruction for malignant tumors of bone
    Andrea Brown
    University Musculoskeletal Oncology Unit, and Department of Rehabilitation Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Arch Phys Med Rehabil 84:62-8. 2003
    ..Baseline job demand and living environment (rural vs urban, P=.001) were predictive by logistic regression. CONCLUSIONS: Patients with physically demanding jobs, and those living rurally, are at greatest risk for altered work status...
  39. ncbi Osseous invasion by soft-tissue sarcoma: assessment with MR imaging
    David A Elias
    Departments of Diagnostic Imaging, Pathology and Laboratory Medicine, Mount Sinai Hospital and the University Health Network, University of Toronto, 600 University Ave, Toronto, Ontario, Canada M5G 1X5
    Radiology 229:145-52. 2003
    ..001). CONCLUSION: On T1- and T2-weighted MR images, findings of cortical and medullary signal intensity change and cortical destruction were sensitive and specific for detection of osseous invasion by soft-tissue sarcoma...
  40. ncbi Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma
    Kårstein Måseide
    Ontario Cancer Institute Princess Margaret Hospital, Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 10:4464-71. 2004
    ..The aim of this study was to quantify the extent of CA IX expression and to investigate whether CA IX is a marker for poor prognosis in soft tissue sarcoma patients at high risk of developing metastasis...
  41. ncbi Periprosthetic bone remodeling around a prosthesis for distal femoral tumors: longitudinal follow-up
    Aileen M Davis
    Toronto Rehabilitation Institute, Toronto, Canada
    J Arthroplasty 20:219-24. 2005
    ..Key words: DEXA, stress shielding, uncemented endoprothesis, tumor, bone loss...
  42. ncbi Maternal and neonatal outcomes in pregnancies complicated by bone and soft-tissue tumors
    Cynthia Maxwell
    Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Obstet Gynecol 104:344-8. 2004
    ..Primary bone and soft-tissue tumors occur rarely in pregnancy. The objective of this study was to describe the outcome of a large cohort of pregnant patients with these rare tumors...
  43. ncbi Outcome in two groups of patients with allograft-prosthetic reconstruction of pelvic tumor defects
    Gordon P Beadel
    University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Orthop Relat Res 438:30-5. 2005
    ..Group 2 patients had no infections and better functional results. LEVEL OF EVIDENCE: Therapeutic study, Level IV-1 (case series). See the Guidelines for Authors for a complete description of levels of evidence...
  44. ncbi A mutant PTH/PTHrP type I receptor in enchondromatosis
    Sevan Hopyan
    Program in Developmental Biology, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada
    Nat Genet 30:306-10. 2002
    ..The mutant receptor constitutively activates Hedgehog signaling, and excessive Hedgehog signaling is sufficient to cause formation of enchondroma-like lesions...
  45. ncbi Aseptic loosening is uncommon with uncemented proximal tibia tumor prostheses
    Michael N Flint
    University Musculoskeletal Oncology Unit, Mount Sinai Hospital, 476E-600 University Avenue, Toronto, Ontario M5G 1X5, Canada
    Clin Orthop Relat Res 450:52-9. 2006
    ..Aseptic loosening is uncommon with uncemented proximal tibia reconstruction, but decreasing other complications at this location remains challenging. LEVEL OF EVIDENCE: Therapeutic study, level IV-1 (case series)...
  46. ncbi Bone invasion in extremity soft-tissue sarcoma: impact on disease outcomes
    Peter C Ferguson
    University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, Canada
    Cancer 106:2692-700. 2006
    ..The purpose of the current study was to evaluate histologic bone invasion as a predictor of oncologic outcome in extremity soft-tissue sarcoma (STS) patients presenting to a specialty sarcoma center between 1986 and 2001...
  47. ncbi Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation
    Tri Dung Tiet
    The Hospital for Sick Children, 555 University Ave, Suite S107, Toronto, Ontario, Canada, M5G 1X8
    Am J Pathol 168:321-30. 2006
    ..Our data raise the intriguing possibility that Hedgehog blockade could serve as an effective treatment for chondrosarcoma, a tumor for which there are currently no universally effective nonsurgical management options...
  48. ncbi Uncemented tumor endoprostheses at the knee: root causes of failure
    Anthony M Griffin
    University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Orthop Relat Res 438:71-9. 2005
    ..LEVEL OF EVIDENCE: Therapeutic study, level IV-1 (case series)...
  49. ncbi Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis
    Wenyong Chen
    Cancer Biology Program, Johns Hopkins Medical Institutions, 1650 Orleans Street, Baltimore, MD 21231, USA
    Cancer Cell 6:387-98. 2004
    ..Our results indicate the importance of genes altered only through epigenetic mechanisms in cancer progression in conjunction with genetically modified tumor suppressor genes...
  50. ncbi Large segment allograft survival is improved with intramedullary cement
    Craig H Gerrand
    North of England Bone and Soft Tissue Tumour Service, Newcastle-upon-Tyne, United Kingdom
    J Surg Oncol 84:198-208. 2003
    ....
  51. ncbi Patched-one or smoothened gene mutations are infrequent in chondrosarcoma
    Taiqiang Yan
    Department of Orthopaedic Oncology, People s Hospital, Beijing University, Beijing, China
    Clin Orthop Relat Res 466:2184-9. 2008
    ..4%) control subjects without cartilage tumors, suggesting it may represent a rare SMO variant. Constitutive activation of the hedgehog signaling pathway in chondrosarcoma is rarely caused by PTCH-1 or SMO mutations. [corrected]..
  52. ncbi Two-stage revision of infected uncemented lower extremity tumor endoprostheses
    Michael N Flint
    Orthopaedic Oncology Unit, Middlemore Hospital, Auckland, New Zealand
    J Arthroplasty 22:859-65. 2007
    ..Two-stage revision of uncemented tumor endoprostheses with retention of a well-ingrown stem can be associated with successful eradication of infection...
  53. ncbi Outcome after pelvic sarcoma resection reconstructed with saddle prosthesis
    Fawzi Aljassir
    McGill University Health Centre, Montreal, Canada
    Clin Orthop Relat Res 438:36-41. 2005
    ..LEVEL OF EVIDENCE: Therapeutic study, Level IV-1 (case series without control group). See the Guidelines for Authors for a complete description of levels of evidence...